ALDEYRA THERAPEUTICS, INC.

ALDX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013
Operating Activities
Net Income $-22.3M $-18.7M $-12.1M $-5.2M $13.1M
Depreciation & Amortization
Depreciation $37.8K $35.8K $18.8K $1.1K
Amortization
Stock-Based Compensation $2.7M $2.8M $2.2M $2.0M $1.7M
Net Cash from Operating Activities $-19.2M $-15.1M $-9.3M $-4.8M $-1.7M
Investing Activities
Capital Expenditures $24.8K $11.8K $86.1K $14.1K
Business Acquisitions
Net Cash from Investing Activities $-10.2M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $37.4M
Net Change in Cash $8.0M $-2.6M $6.1M $5.3M $2.0M
Free Cash Flow $-19.2M $-15.2M $-9.4M $-4.8M
← Newer Page 2 of 2 Older →